Mechanistic Insight into Diosmin-Induced Neuroprotection and Memory Improvement in Intracerebroventricular-Quinolinic Acid Rat Model: Resurrection of Mitochondrial Functions and Antioxidants

Mian Huang,1 Navpreet Singh,2 Ritu Kainth,2 Mohammad Khalid,3 Ajay Singh Kushwah*2, and Manish Kumar*4

1Department of Neurology, Wuhan Third Hospital (Tongren Hospital Affiliated to Wuhan University), No. 216, Guanshan Dadao, Wuhan, Hubei Province 430070, China
2Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Punjab 140111, India
3Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
4Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India

Correspondence should be addressed to Ajay Singh Kushwah; kushwah_ph05@yahoo.co.in and Manish Kumar; mkpharmacology@gmail.com

Received 9 January 2022; Accepted 14 February 2022; Published 8 March 2022

Academic Editor: Ruchika Garg

Copyright © 2022 Mian Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neurodegeneration is the final event after a cascade of pathogenic mechanisms in several brain disorders that lead to cognitive and neurological loss. Quinolinic acid (QA) is an excitotoxin derived from the tryptophan metabolism pathway and is implicated in several ailments, such as Alzheimer’s, Parkinson’s, Huntington’s, and psychosis disease. Diosmin (DSM) is a natural flavonoid possessing such properties that may halt the course of neurodegenerative progression. In past studies, free radical scavenging, along with properties, such as antihyperglycemic, anti-inflammatory, and vasoactive properties, of DSM were pragmatic. Hence, in the current experimentations, the neuroprotective activity of DSM was investigated in the QA rat prototype. QA was administered through the intracerebroventricular route (QA-ICV) in rats on day one, and DSM (50 and 100 mg/kg, intraperitoneal route) was given from day 1 to 21. Memory, gait, sensorimotor functions, and biomarkers of oxidative mutilation and mitochondrial functions were evaluated in the whole brain. Results showed significant deterioration of sensorimotor performance, gait, and working- and long-term memory in rats by QA-ICV. These behavioral anomalies were significantly attenuated by DSM (50 and 100 mg/kg) and donepezil (standard drug). QA-ICV-induced decrease in body mass (g), diet, and water ingestion were also attenuated by DSM or donepezil treatments. QA-ICV inhibited mitochondrial complex I and II activities that caused an increase in oxidative and nitrosative stress along with a reduction in endogenous antioxidants in the brain. DSM dose-dependently ameliorated mitochondrial functions and decreased oxidative stress in QA-ICV-treated rats. DSM can be a possible alternative in treating neurodegenerative disorders with underlying mitochondrial dysfunction pathology.

1. Introduction

Progressive neurodegeneration with concomitant cognitive and neurological deficits are the major manifestations of several brain ailments, such as Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s disease (HD). Synaptic waning and impaired long-lasting potentiation because of the decreased expression of neurotrophins (e.g., neurotrophic factors, abrineurin, and neural development factors), neurochemical aberrations (e.g., acetylcholine, glutamate, monoamines, and γ-aminobutyric acid), neuropeptides (e.g., oxytocin, substance P, somatostatin, and orexin), and changes in the internal milieu of the brain leads to deterioration of short term and long-term memory [1]. Excitatory
Evidence-Based Complementary and Alternative Medicine

pathways mediated by glutamatergic receptors are often allied with the consolidation of long-term memory in the hippocampus and cortex of the brain [2]. Receptors like N-methyl D-aspartate (NMDARs) are an essential component of long-lasting potentiation and depression, and calcium-influx via NMDARs and voltage-gated calcium (Ca2+) channels (VGCCs) strengthens the synapse. However, excessive excitatory drive in the brain culminates in brain atrophy via free radicals, proinflammatory cytokines, and activation of cell death pathways [3, 4].

Quinolinic acid (QA) is a product of the kynurenine pathway of tryptophan metabolism and is an endogenous ligand of NMDARs [5]. Although tryptophan is obligatory for serotonin and tryptamine biosynthesis, > 95% of tryptophan is metabolized through the kynurenine pathway [6]. Kynurenine pathway metabolites (e.g., kynurenic acid) are neuroactive, including QA, and they are implicated in schizophrenia, AD, and HD [7]. QA activates the immune system (microglia and astrocytes), increasing the expression of chemotactic factors (e.g., monocyte chemoattractant protein-1, RANTES) and instigating free radicals. An increase in the blood-brain barrier (BBB) penetrability prevents the shielding effect against QA, which predisposes the brain to excess QA influx. QA is a metabolic inhibitor that makes it a potent neurotoxin [8]. QA inhibits monoamine oxidase-B (MAO-B), gluconeogenesis (via phosphoenolpyruvate carboxykinase), creatine kinase, mitochondrial complexes, cellular respiration, and decreases ATP levels [9]. QA can augment oxidative stress and decline antioxidants in an NMDAR-dependent or -independent manner. QA-Fe2+ interaction instigates free radicals, leading to lipid peroxidation and DNA mutation substantiated by an upsurge in hydroxyl radicals, poly (ADP-ribose) polymerase (PARP) activity, and lactate dehydrogenase (LDH) activity [10]. Clinical findings also revealed that QA is enhanced in the brain, blood, and cerebrospinal fluid (CSF) of AD and HD patients [5]. Findings in the past indicate that QA can induce cognitive deficits and other behavioral abnormalities in experimental animals [11]. Recent studies revealed that natural products could ameliorate the symptoms of cognitive dysfunction and improve the therapeutic outcome in neurodegenerative disorders [12, 13].

A flavonoid glycoside, diosmin (3′,5,7-trihydroxy-4′-methoxy flavone-7-rhamnoglucoside), is frequently extant in the pericarp of citrus fruits (Rutaceae) [14]. Diosmin (DSM) consists of a disaccharide group (6-O-(α-L-rhamnopyranosyl)-β-D-glucopyranosyl) attached with the aglycone moiety (diosmetin) through glycosidic linkage and can be biosynthesized from hesperidin. Intestinal flora transforms DSM glycoside to aglycone moiety, which is then rapidly absorbed through the gastrointestinal tract. In humans, the half-life of DSM is 26 to 43 hours when given through the oral route [15]. It is a vasoactive drug that improves microcirculation, lymphatic drainage, and enhances the flexibility of veins by attenuating norepinephrine metabolism by catechol-O-methyl transferase. DSM abrogates microvascular permeability, leukocyte extravasation, and the appearance of adhesion molecules, such as ICAM-1 and VCAM-1 [14, 15]. Several studies indicated free radical runnaging and immune harmonizing properties of DSM in the brain [16, 17]. Clinical evidence recommends that DSM is a well-tolerable, safe, and nontoxic drug [15]. In nutriceuticals, DSM (Daflon) is often proposed to treat venous disorders, including hemorrhoids and hyperglycemic conditions. Previous findings indicated that DSM could stimulate insulin release from the β-cells, carbohydrate metabolism, and the expression of glucose transporters (GLUTs). Also, it decreases diabetic complications [15]. It attenuates dyslipidemia and hepatic gluconeogenesis [16]. In previous studies, DSM improved cognitive functions, attenuated the symptoms of schizophrenia, and showed neuroprotective effects in experimental animals [16–19]. Sawmiller et al. [20], in a study, noted DSM-mediated decrease in amyloid β and tau hyperphosphorylation by attenuating glycogen synthase kinase 3β in the 3×Tg-AD mouse model. These findings aptly signify that DSM has the potential to ameliorate brain dysfunctions against QA. In this study, QA was used to induce dementia and other neurological deficits in rats. QA can act as a potent neurotoxin that inhibits several pathways and molecular mechanisms in the brain to induce progressive neurodegeneration and brain atrophy. The contemporary investigation was designed to explore the outcomes of DSM in the QA-ICV rat prototype.

2. Material and Methods

2.1. Experimental Animals. This research was permitted by IAEC under protocol no. ASCB/IAEC/14/20/145. Albino Wistar rats (either sex, 200 g to 250 g, age 8 to 9 months old) were retained in typical size polypropylene cuboidal enclosures under artificial settings of temperature (23 ± 2°C), 12:12 hours dark/light sequences, and humidity (40 ± 10%) within the institutional animal house. The rodents were fed a standard nourishing foodstuff (Ashirwad Manufacturers, Punjab) and purified water at will. All animal procedures are exclusively performed as per the guidelines of CPCSEA, GOI, New Delhi. The animal custodian and handlers were blinded concerning different therapeutic regimens facilitated to animal cohorts. Investigative animal trials were executed, succeeding at least a single fortnight of familiarization duration. All investigations using animals were performed between 0900- and 1600-hours course in a day.

2.2. Drugs and Chemicals. Diosmin (DSM: 520-27-4), quinolinic acid (QA: 89-00-9), and standard analytes were acquired from Merck (India). Sodium dihydrogen phosphate (NaH₂PO₄), sodium hydroxide (NaOH), potassium phosphate dibasic (K₂HPO₄), nitrobutetrazolium (NBT), phenazine methosulphate (5-methylphenazinium methyl sulphate), ethylenediaminetetraacetic acid (EDTA), bovine serum albumin (BSA), 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulphonic acid (HEPES), 1,2-bis-[2-[bis(carboxymethyl) amino]ethoxy]ethane (EGTA), riboflavin, sodium cyanide (NaCN), natriumazid (NaN₃), tetrasodium pyrophosphate, hydrogen peroxide (H₂O₂), NADH disodium (DPNH), NADPH tetrasodium (Coenzyme II reduced tetrasodium...
2.3. Intracerebroventricular Injection of Quinolinic Acid. Animals were subjected to anesthesia by administering intraperitoneally (i.p.) ketamine (90 mg/kg) and xylazine (10 mg/kg) cocktail using sterile water for injection. The body was laid in the prone position on a warm heating pad (10 mg/kg) cocktail using sterile water for injection. LXıhe ketamine (90 mg/kg) and xylazine (i.p.) in rats over 5 to 6 minutes duration with the volume of injection 5 µl ICV-vehicle [22]. After the inoculation of the whole drug, the microneedle was not dislodged for 4 to 5 minutes. For footprints, rat feet were immersed in four diverse colored nontoxic food dyes and were permitted to run on an inclined walkway (70 cm × 10 cm × 8 cm). The runway base was enclosed with a cellulose sheet of white color. The rats were motivated to a dim uphill section at the end of the runway to obtain clear footprints. The dye was gently removed from each animal using lukewarm water after the trials. The footprints were scanned, and the “stride length” was measured by means of a standard ruler. Stride length was quantified by calculating the distance between the sequential placements of the identical rat’s paw [11].

2.8. Novel Object Recognition Task (NORT). Standard protocol was followed as given by Kumar and Bansal [23]. NORT is an unprofitable and nonhostile exteroceptive archetypal employed to assess the working type recollective memory exploited through the impulsive probing conduct of rodents. The investigation is performed in a rooftop-open plywood cuboidal vessel (80 cm × 42 cm × 62 cm), positioned in a quiet area, illuminated by a 60W LED to manage consistent brightness in the vessel. Cylinder (white)-, pyramid (red)-, and cube (black)-shaped (12 cm tall) wooden items (in identical triplets) were solid and of enough weight to render them immobile by rodents. NORT was performed on the 16th day in 3 stages (S): acclimatization (S1),
acquisition (S2), and novel object recognition examination (retention) stage (S3). During S1, three successive days before the trials were issued to discover the vacant floor base of the vessel (5 minutes) by the rats. Upon the completion of S1, the individual animal was habituated to any one set of solid items in the learning stage (S2). Twin alike things were positioned in 2 arbitrarily selected contrary angles of the vessel (9 cm to 11 cm gap from the side ramparts). Separately, a rodent was positioned at the center of the vessel facing opposite to the two solid items and was permitted to discover the two similar items for 5 minutes. Guiding the snout near the object at ≤2–3 cm distance or physical contact with the item with the muzzle was supposed as investigative conduct. After S2, the rodent was housed in a home cage trailed by an intertrial recess (ITR) of 60 minutes. Any single solid item offered in S2 was swapped by a different solid item, and the rodents were presented again to the twin items, i.e., a replica of the acquainted item and the different item. The whole of the amalgamations and positions of the items were offset to abate likely prejudice instigated by a penchant for certain settings or items. The vessel and solid items were meticulously wiped (ethyl alcohol 15% and dry cloth) after every investigation to curb the odorous signs. The period of investigation to the novel item was meticulously wiped (ethyl alcohol 15% and dry cloth) after every investigation to curb the odorous signs. The duration expended investigating the two similar items for 5 minutes. Guiding the snout near the object at ≤2–3 cm distance or physical contact with the item with the muzzle was supposed as investigative conduct. After S2, the rodent was housed in a home cage trailed by an intertrial recess (ITR) of 60 minutes. Any single solid item offered in S2 was swapped by a different solid item, and the rodents were presented again to the twin items, i.e., a replica of the acquainted item and the different item. The whole of the amalgamations and positions of the items were offset to abate likely prejudice instigated by a penchant for certain settings or items. The vessel and solid items were meticulously wiped (ethyl alcohol 15% and dry cloth) after every investigation to curb the odorous signs. The period of investigation to the novel item was meticulously wiped (ethyl alcohol 15% and dry cloth) after every investigation to curb the odorous signs.

2.9. Morris Water Maze (MWM). The standard protocol was followed, as given by Kumar and Bansal [25]. MWM judges the spatial memory by swimming trials, in which the rodent finds an escape route to a concealed podium. A black colored circular tank (2 m diameter, 0.6 m height) had water (25 ± 1°C) filled to a depth of 0.3 m. This aquatic reservoir was separated clockwise into 4 similar regions (R1, R2, R3, and R4) using two nylon fibers, secured perpendicularly on the upper perimeter of the tank. A dais (10.5 cm × 10.5 cm) was positioned underwater (1 cm underneath water) in the reservoir region R4. The spot of the dais persisted intact all over the acquisition period. Every single rat was presented with four serial acquisition rounds (5 minutes ITR) every day. The rodent was gently released into the aquatic reservoir facing the tank wall, with the site varying with every single trial from R1-R4, R2-R1, R3-R2, and R4-R3 on days 1 to 4, respectively, and it was permitted 120 seconds to detect the underwater podium. The rodents continued to rest on the podium for 20 seconds. A failure to detect the platform within 120 seconds indicated the manual placement of rats on the platform, and then they were permitted 20 seconds on the platform. Escape latency time (ELT) is the duration (s) of discovering the concealed dais in the aquatic reservoir. Spatial learning was marked by day one vs. day four ELT. In the probe trial (5th day), the rodents investigated the reservoir for 120 seconds but were deprived of the podium. The
mean duration expended in the entire reservoir (4 regions) was recorded. The mean duration expended in R4 (TSTQ: time spent in target quadrant) probing for the concealed podium was deemed as an index of reference memory. The comparative setting of the tank relative to the items in the laboratory that act as visual signs and the investigator’s position remained undisturbed [26].

2.10. Estimation of Biochemical Parameters. After completing the behavioral examinations, the complete brain of the rats was garnered and positioned on pulverized ice cubes, followed by bathing with freezing sterilized saline (isotonic 308 mOsmol/l NaCl) to remove the remains and blood. Homogenization of the entire brain was instantly accomplished in a freezing separation buffer (pH 7.4) with the composition 215 mM D-mannitol, 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, 1 mM 1,2-bis[2-[bis(carboxymethyl)amino]ethoxy]ethane, 75 mM saccharose, and 0.1% BSA. The homogenate was centrifugated at 4°C using 13000 × g force for 5 minutes. The pellet was rejected, and the supernatant was separated into two portions and was recentrifuged (4°C) at 13000 × g force for 5 minutes. The crude mitochondrial pellet was separated and again centrifuged in a separation buffer with 1,2-bis[2-[bis(carboxymethyl)amino]ethoxy]ethane at 12,500 × g for 11 minutes (4°C). The semisolid deposit so obtained comprising uncontaminated mitochondria was resuspended in a separation buffer (pH 7.4) containing 75 mM saccharose, 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, and 215 mM D-mannitol [27]. Later, the mitochondrial fraction of the whole-brain homogenate was used to determine the biochemical markers using standard methods.

2.11. Estimation of Mitochondrial Complex

2.11.1. NADH: Ubiquinone Oxidoreductase Activity. The rate of complex I (NADH dehydrogenase) activity was quantified (nmol NADH oxidized/minute/mg protein) by following the technique of King and Howard [28]. The oxidative generation of NAD+ from NADH is accompanied by cytochrome c reduction. The assay blend consisted of cytochrome c (105 mM), 6 mM β-nicotinamide adenine dinucleotide (DPNH) dissolved using 2 mM diglycine buffer, and diglycine buffer (pH 8.5). A dissolvable mitochondrial fraction was incorporated in the assay concoction to trigger the reaction. The variation in optical density (O.D.) at \( \lambda_{\text{max}} = 550 \text{ nm} \) was followed for 120 seconds.

2.11.2. Succinate: Ubiquinone Oxidoreductase Activity. The rate of succinate dehydrogenase (complex II) activity was quantified (nmol succinate oxidized/minute/mg protein) by following the technique of King [29]. Succinic acid oxidation is triggered by a mock electron receiver, potassium cyanoferrate (K₅Fe(CN)₆). The assay blend comprised of succinic acid (0.63 M), 1% BSA, K₅Fe(CN)₆ (0.036 M), and Na⁺-K⁺ [PO₄]²⁻ buffer (0.23 M, pH 7.6). A dissolvable mitochondrial fraction was incorporated in the assay concoction to trigger the reaction. The variation in O.D. at \( \lambda_{\text{max}} = 420 \text{ nm} \) was followed for 120 seconds.

2.12. Determination of Oxidative Stress Biomarkers

2.12.1. Thiobarbituric Acid Reactive Substances (TBARS). To evaluate TBARS (nmol per mg protein) [30], the analyze combination (concluding quantity ∼4 ml) comprising 0.10 ml homogenized brain, 1.51 ml 4,6-dihydroxy-2-mercaptopyrimidine (0.8%), 200 µl SLS (8.18%), 1.49 ml glacial acetic acid (21%, pH 3.51), and 0.71 ml deionized water was subjected to water-bath heating at 96°C for 60 minutes. A 15:1 ratio butyl alcohol/azabenzene (5.1 ml) was supplemented in analyze concoction that was centrifugated at 4,000 × g power (10 minutes), and the supernatant was secluded. With a twin-beam UV1700 spectrophotometer (Shimadzu, Japan), chromophore malondialdehyde-4,6-dihydroxy-2-mercaptopyrimidine O.D. was appraised at a wavelength \( \lambda_{\text{max}} = 532 \text{ nm} \), and \( \varepsilon = 1.56 \times 10^{5} / \text{M/cm} \) (molar extinction coefficient) was applied to compute 4,6-dihydroxy-2-mercaptopyrimidine adducts.

2.12.2. Reduced Glutathione (L-γ-Glutamyl-L-Cysteinyl-glycine) Levels. Ellman’s [31] procedure was implemented to appraise L-glutathione (GSH) content. The test concoction encompassing homogenate (1.1 ml) and 1 ml of 4% 2-hydroxy-5-sulfobenzoic acid (5-SSA) was centrifugated (4°C) for 11 minutes at 2,500 × g power. Later, 2.8 ml Na⁺-K⁺ [PO₄]²⁻ buffer (51.2 mM, pH 7.77) and 0.21 ml 3-carboxy-4-nitrophenyl disulfide (0.12 mM, pH 7.89) was blended with the above-separated supernatant (0.12 ml). Tripeptide (µmol GSH per mg protein) was quantified with the twin-beam UV1700 spectrophotometer (\( \lambda_{\text{max}} = 412 \text{ nm} \)). applying \( \varepsilon = 1.36 \times 10^{3} / \text{M/cm} \).

2.12.3. Glutathione Peroxidase Activity. The activity of glutathione peroxidase (GPx) (EC 1.11.1.9) was appraised by implementing the technique of Mohandas et al. [32]. The analyze blend comprised of 100 µl of 10% homogenate, 100 µl sodium azide (1.11 mM), 100 µl EDTA (1.13 mM), 40 µl glutathione-disulfide reductase (GSR, 11U/ml) (EC 1.8.1.7), 10 µl H₂O₂ (0.28 mM), 40 µlL-γ-glutamyl-L-cysteinyl-glycine (1.2 mM), 100 µl coenzyme II reduced tetrasodium salt (0.22 mM), and 0.12 M 1.49 ml Na⁺-K⁺ [PO₄]²⁻ buffer (pH 7.4) in an entire quantity of 2000 µl. The loss of coenzyme II-reduced tetrasodium at \( \lambda_{\text{max}} = 340 \text{ nm} \) was documented at a temperature of 25°C. GPx rate was computed as nmol NADPH oxidized/minute/mg protein by means of \( \varepsilon = 6.22 \times 10^{3} / \text{M/cm} \).

2.12.4. Superoxide Dismutase Activity. The rate of SOD (EC 1.15.1.1) action (units per mg protein) was considered by the procedure of Kakkar et al. [33]. The reaction concoction involved 0.3 ml homogenate, 100 µl 5-methylphenazinium methyl sulphate (197 µM), and 1.3 ml sodium diphosphate tetrabasic (0.066 mM, pH 7.2). The reaction was commenced
using 200 μl of β-nicotinamide adenine dinucleotide (DPNH) (780 μM) and halted 60 seconds later using 1 ml glacial CH₂COOH in this blend. Chromogen quantity generated was computed by noting the color strength at λ <sub>max</sub> = 560 nm.

2.12.5. Catalase Activity. To assess the rate of catalase (EC 1.11.1.6) action, the O.D. discrepancy (λ <sub>max</sub> = 240 nm) of the analyze concoction (3.0 ml) comprising 50 μl investigating sample, 1.22 ml H₂O₂ (0.03 M) in Na⁺–K⁺ [PO₄]<sub>2</sub>⁻ buffer (pH 7.91, 0.06 M), and 1.63 ml of 0.06 M Na⁺–K⁺ [PO₄]<sub>3</sub>⁻ buffer (pH 7.1) was recorded. Catalase activity (μmol H₂O₂ decayed per minute per mg protein of brain) was computed by applying ε = 43.6/M/cm [34].

2.12.6. Whole Nitrites Level. The technique of Sastry et al. [35] was implemented to evaluate entire brain nitrites (μmol per mg of brain protein). In test tubes encompassing 100 μl investigative sample, 145 mg amalgam of copper–cadmium, 500 μl H₂CO₃ buffer (pH 8.89), 0.44 M 100 μl NaOH, and 119.8 mM 400 μl ZnSO₄ were centrifuged at 4,500 × g power for 10 minutes, and the superfluous upper liquid (supernatant) was secluded. Griess chemical (50 μl) of the analyze was mixed with 1 ml glacial CH₃COOH in this blend. Chromogen quantity generated was computed by noting the color strength at λ <sub>max</sub> = 548 nm wavelength) was noted employing a twin-beam UV1700 spectrophotometer (Shimadzu). A typical curve of nitrous acid sodium (0.02–0.2 mM) was designed, and the entire nitrite was equated.

2.12.7. Determination of Total Proteins. The overall protein level (mg/ml of homogenate) was computed by means of a typical curvature graph of bovine serum albumin with the solution strength ranging from 0.3 to 3.8 mg/ml. The examination combination was organized with 250 μl homogenate, 5.1 ml Lowry’s reagent, Na⁺–K⁺ [PO₄]<sub>2</sub>⁻ buffer (900 μl), and 1.1 N 500 μl FCR. The discrepancy of O.D. was observed at λ <sub>max</sub> = 650 nm [36].

2.13. Brain Sections Histopathology. By means of a gravity-fed diffusion setup, rats were intracardially (via left ventricle) diffused with 10% neutral buffered formaldehyde (10% NBF) solution and acutely anesthetized. Hippocampus and cortical sectors are immersed in a fixative (10:1 fixative: tissue proportion), namely 10% NBF for one week (4°C), accompanied by 0.04% natriumiazid (pH 7.4). Ethyl alcohol (70%) was employed as a packing solution for fixed tissue portions kept at 4°C. A microtome cutter (rotation type) was employed to acquire thin portions (8.0 μm), which were then tinted with colorant hematoxylin and eosin (H&E). The slides were made permanent by means of DPX-resin, which were later cover-slipped and inspected through an optical microscope (binocular) at ×40 magnifications.

2.14. Statistical Analysis. A skilled experimenter blinded to miscellaneous drug regimens given to animal cohorts scrutinized and evaluated the data. Outliers were not pragmatic (Grubb’s test) in the data, and the Kolmogorov-Smirnov test and Levene’s test confirmed the normal distribution of variables and homogeneity of variance (HOV <p>0.05, Levene’s test), respectively. Otherwise, in case of unequal variance (HOV <p>0.05, Levene’s test), Welch’s ANOVA (p <0.05, F<p>statistic) and Games–Howell post hoc tests can be applied. The means of normally distributed variables were scrutinized and related by one-way or repeated measures of two-way analysis of variance (ANOVA). In the case of ANOVA, outcomes are significant (p <0.05) in F-statistics, multiple comparison tests, namely Tukey’s HSD (honest significant difference) or Bonferroni, were applied. Statistical significance was deemed at p <0.05, and the results were stated as mean± Standard Error of Mean (SEM).

3. Results

3.1. Outcomes of DSM on Body Mass (g), Diet, And Water Ingestion of Rats Administered QA-ICV. Body weights, feed, and water ingestion were analyzed weekly, starting from day 1. A significant reduction (p <0.001) in body mass (g), feed, and water intake on day 7, 14, and 21 was pragmatic in rats subjected to QA-ICV injection on day 1 when compared to sham counterparts (Figure 2). DSM (100 mg/kg) dosing caused a significant increase in the body weight (day 7 <p>0.05, day 14 <p>0.01, day 21 <p>0.001), feed (day 7 <p>0.05, day 14 <p>0.01, day 21 <p>0.001), and water intake (day 7 <p>0.01, day 14 <p>0.05) in rats against QA-ICV. DSM (50 mg/kg) also significantly attenuated QA-ICV-triggered decrease in the body weight (day 21 <p>0.05) and feed intake (day 7 <p>0.01) of rats relative to rats that have lone QA-ICV injections. QA-ICV- and DNP-treated rats disclosed a significant escalation in body mass (g) (day 7 <p>0.05, day 14 <p>0.001, day 21 <p>0.001), feed (day 7 <p>0.001, day 14 <p>0.01, day 21 <p>0.001), and water intake (day 7, 14, 21 <p>0.01) relative to rats that remained exposed to lone QA-ICV.

3.2. Effect of DSM on Locomotion, Motor Coordination, and Gait of Rats against QA-ICV. In this study, the locomotor activities of animals were not affected by QA-ICV or drug treatments. QA group depicted no significant change in the mean counts per 5 minutes in the actophometer apparatus in comparison to the sham group (Figure 3(a)). Rotarod and footprint analysis were used to evaluate the sensorimotor performance and gait of rats. Results showed that QA-ICV significantly hampered (p <0.001) motor coordination (Figure 3(b)) and gait (Figure 3(c)) of rats, reflected by a decrease in latency to fall from the revolving shaft and the stride length of rats in footprint analysis in comparison to sham counterparts. QA + DSM50 and QA + DSM100 groups portrayed a noteworthy increase in the falling latency (p <0.05, p <0.01) and stride length (p <0.05, p <0.001) relative to QA group. DNP treatment significantly attenuated QA-ICV-triggered decrease in latency to fall (p <0.001) and stride length (p <0.001) when compared to rats that were given QA-ICV alone. Furthermore, DSM (100 mg/kg)}
treatment displayed a significant improvement ($p < 0.01$) in gait relative to DSM (50 mg/kg) in rats subjected to QA-ICV.

3.3. Effect of DSM on Working Memory and Spatial Long-Term Memory of Rats against QA-ICV. A decrease in discrimination index (%) in NORT corroborated a decrease in the working type memory. A gradual increase in ELT over 4 days of training trials and a decrease in TSTQ in the retrieval trials (conducted 24 hours after last training trial) in MWM denoted long-term memory loss in rats. In this study, rats that were exposed to QA-ICV treatment alone indicated a noteworthy decline ($p < 0.001$) in the discrimination index (%) relative to sham (Figure 4(a)). In the MWM test, day 17 training trials revealed no significant alteration in ELT among different groups, however, on day 18, marked change in ELT was noted. QA cohort displayed a substantial ($p < 0.001$) increase in ELT (day 18–20) (figure 4(b)) and decrease in TSTQ (day 21) (Figure 4(c)) relative to sham counterparts. Treatment with DSM (100 mg/kg)-attenuated QA-ICV prompted diminution in discrimination index (%) ($p < 0.001$), increase in ELT (day 18 $p < 0.05$, day 19 $p < 0.01$, day 20 $p < 0.001$), and decrease in TSTQ ($p < 0.001$) when compared with the rats that have undergone QA-ICV injection alone. QA + DSM50 cohort exhibited a substantial upsurge in discrimination index (%) ($p < 0.001$), decrease in day 20 ELT ($p < 0.01$), and increase in TSTQ ($p < 0.001$) relative to the QA group. DNP treatment enhanced the discrimination index (%) ($p < 0.001$), decreased ELT (day 18 $p < 0.01$, day 19 $p < 0.001$, day 20 $p < 0.001$), and increased TSTQ ($p < 0.001$) in rats that were administered QA-ICV in comparison to vehicle-treated QA-ICV rats. Furthermore, DSM (100 mg/kg)-repeated injections disclosed a substantial

![Figure 2: Outcomes of diosmin (DSM) treatment (doses 50 and 100 mg/kg) for 21 repeated days on the body mass (g), diet, and water consumption of rats exposed to QA-ICV on 1st day. Statistical scrutiny of (a) body weight (g), (b) diet ingestion (g), and (c) water consumption (ml) was done each week using repeated measures of two-way ANOVA and Bonferroni post hoc test. Data are presented as mean ± SEM (n = 5). $^{***}p < 0.001$ vs. Sham; $^*p < 0.05$, $^{**}p < 0.01$, $^{***}p < 0.001$ vs. QA group. Body weight: $[F_{(12,80)} = 3.54, p < 0.001]$, feed intake: $[F_{(12,80)} = 3.04, p < 0.001]$, water intake: $[F_{(12,80)} = 1.30, p < 0.001]$.](image)
improvement in memory functions relative to DSM (50 mg/kg) in rats subjected to QA-ICV.

3.4. Outcomes of DSM on Brain Mitochondrial Complex in QA-ICV Injected Rats. Mitochondrial activity in the whole-brain homogenate was evaluated after behavioral trials. Results showed a significant decline \((p < 0.001)\) in the complex I/II rates in the mitochondrial fraction of the brain homogenate by QA-ICV relative to sham (Figure 5). This decrease in complex I/II activity by QA-ICV treatment was attenuated (complex I \(p < 0.05, p < 0.001\); complex II \(p < 0.01, p < 0.001\)) by DSM (50 and 100 mg/kg) given for 21 successive days in comparison to QA-ICV-administered rats that were given drug vehicle treatment alone. DNP significantly enhanced \((p < 0.001)\) the activity of complex I/II in contrast to the vehicle in QA-ICV injected rats.

3.5. Effect of DSM on Brain Mitochondrial Oxidative Stress in QA-ICV Injected Rats. Results exhibited a noteworthy increase \((p < 0.001)\) in the TBARS and total nitrites and a decline in GSH, GPx, SOD, and catalase activities in the mitochondrial fraction of the brain homogenate by QA-ICV relative to sham (Figure 6). This augmentation in the brain TBARS \((p < 0.05, p < 0.001)\) and total nitrites \((p < 0.05, p < 0.01)\) and decline in GSH \((p < 0.05, p < 0.001)\), GPx \((p < 0.05, p < 0.001)\), SOD \((p < 0.01, p < 0.001)\), and catalase \((p < 0.05, p < 0.001)\) activities by QA-ICV treatment was attenuated by DSM (50 and 100 mg/kg) given for 21 uninterrupted days in comparison to QA-ICV-administered rats that were given drug vehicle treatment only. DNP significantly depriated \((p < 0.001)\) brain TBARS and total nitrites accumulation and enhanced \((p < 0.001)\) the activity of GSH, GPx, SOD, and catalase in comparison to the vehicle in QA-ICV-treated rats. Furthermore, DSM (100 mg/kg) treatment displayed a noteworthy depression in lipid peroxidation \((p < 0.001)\) and intensification in endogenous antioxidants, such as GSH \((p < 0.001)\), GPx \((p < 0.01)\), and catalase \((p < 0.05)\), relative to DSM (50 mg/kg) in rats subjected to QA-ICV.

3.6. Effect of DSM on Brain Histopathology in Rats against QA-ICV. In histopathology analysis, major changes in the cellular architecture were observed in the QA group. Sham animals showed no signs of neurodegeneration. QA-ICV treatment caused marked changes highlighted by pyknosis and the blebbing of the plasma membrane in the cortical and the hippocampus (CA 1 and 2) neurons. Treatment of QA-ICV rats with DSM or DNP attenuated the pathological signs of neurodegeneration (Figure 7).

4. Discussion

QA (2,3-pyridine dicarboxylic acid) is an excitotoxin similar to glutamate and is capable of evoking neurodegeneration as its concentration amplifies with age [5]. The antagonists of NMDARs and amino phosphonates can prohibit the neurodegenerative excitotoxicity of QA, which suggests that QA acts through NMDARs in the brain [9]. BBB acts as a protective barrier and limits the neurotoxicity of QA. However, the pieces of evidence indicate enhanced pathological accumulation of QA in diverse neurodegenerative disorders. In the brain, quinolinol phosphoribosyltransferase (QPRT) catabolizes QA to NAD⁺ and carbon dioxide. The activity of QPRT is maximum in the olfactory bulb and lowermost in the cortex, hippocampus, and striatum, where QA may exert neurotoxic action to a great extent in these brain regions. These brain areas are adversely affected in numerous neurodegenerative disorders, such as AD, PD, HD, and schizophrenia that lead to severe cognitive decline [9, 10]. In this study, QA was administered directly through the ICV route to overcome the BBB constraint in the adult rats. DSM is a bioactive natural flavonoid that has shown therapeutic effects against traumatic brain injury [16], scopolamine-induced amnesia [17], apomorphine- and ketamine-induced psychosis [18], and chronic unpredictable mild stress [19]. DSM is capable of enhancing...
glucose metabolism, insulin signaling, and diabetic complications, and it may prevent energy depletion and the ensuing adverse consequences implicated in neurodegenerative disorders [14, 15]. QA inhibits mitochondrial function and energy-producing aerobic respiratory pathways in the brain regions adversely affected in neurodegenerative disorders [5]. Hence, in the present study, rats administered with QA-ICV on day one were exposed to DSM treatment for 21 consecutive days, and biochemical parameters and behavioral functions were assessed.

The findings of this study indicated an increase in oxidonitrosative stress and depreciation of endogenous antioxidant levels by QA-ICV in the mitochondrial fraction of the whole-brain homogenate. Previous studies also indicate NMDAR-dependent and NMDAR-independent increase in free radicals and inflammatory deterioration by QA in experimental animals [5, 9, 10]. In current experiments, QA enhanced lipid peroxidation and total nitrites in the brain. Free radicals and the ensuing modifications in cellular biomolecules, such as lipids, proteins, and DNA, underlie major pathogenic changes in neurodegenerative disorders. Lipid peroxides, such as malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), isoprostanes, and acrolein are highly toxic aldehydes that readily accumulate in the form of bio-adducts and are resistant to autophagic and other mechanisms of removal [37, 38]. A pathogenic rise in these

Figure 4: Effect of diosmin (DSM) treatment (doses 50 and 100 mg/kg) on working memory and spatial long-term memory of rats against QA-ICV was evaluated using novel object recognition task (NORT) and Morris water maze (MWM), respectively. Statistical analysis of (a) discrimination index (%) in NORT, (b) escape latency time (ELT) in training trials using MWM, and (c) time spent in target quadrant (TSTQ) in retention trials using MWM. One-way ANOVA and Tukey’s HSD post hoc test was used for statistical analysis. For time course data (ELT) repeated measures of two-way ANOVA and Bonferroni post hoc test were used. Data are presented as mean ± SEM ((n) = 5). ***p < 0.001 vs. Sham group; *p < 0.05, **p < 0.01, ***p < 0.001 vs. QA group; #p < 0.05, ##p < 0.01 QA + DSM100 vs. QA + DSM50. DI(%): [F(4,24) = 68.15, p < 0.001], ELT: [F(12,80) = 2.21, p < 0.001], TSTQ: [F(4,24) = 86.2, p < 0.001].

Evidence-Based Complementary and Alternative Medicine 9
insoluble adducts breach the integrity of the cell, which leads to a loss of internal homeostasis, leakage of internal components, and cell death [38]. Furthermore, an increase in nitrates directly correlates with the level of nitric oxide release in the brain of rats. The administration of QA-ICV on the first day instigated a noteworthy escalation in nitrates in the brain of rats. Nitric oxide is a gaseous neurotransmitter that participates in synaptic modulation and long-
term potentiation by acting in a rearward manner through NMDARs [39, 40]. Nitric oxide is biosynthesized by nitric oxide synthase (NOS- neuronal) in response to the activation of postsynaptic NMDARs. An influx of calcium ions through postsynaptic NMDARs activates neuronal NOS, leading to the generation of nitric oxide that stimulates presynaptic glutamate release in the synapse. However, excessive NMDAR activation and the resulting overt intracellular influx of calcium ions and nitric oxide biosynthesis leads to a rise in the reactive oxygen species (ROS), such as alkoxyl (RO·), superoxide (O2−), peroxyl (RO2·), hydroxyl radicals (OH·), and hydrogen peroxide (H2O2), and reactive nitrogen species (RNS), such as nitrous anhydride (N2O3), peroxynitrite (ONOO−), and nitrogen dioxide (NO2) [41–43]. RNS modifies proteins, leading to protein nitrosylation and the formation of S-glutathiois and nitrosothiols. Nitric oxide participates in vascular damage (e.g., BBB and ischemia injury) and inflammatory response by the activation of macrophages, astrocytes, matrix metalloproteinases (MMPs), and adhesion molecules [44, 45]. Peroxynitrites cause the nitration of guanine nucleotides, resulting in DNA single-strand rupture, trigger the PARP pathway, and also prohibit DNA repair enzymes [46]. Nitric oxide inhibits cytochrome c oxidase and thereby suppresses mitochondrial ATP production [39]. Hence, excess nitrates accumulation can cause an energy-deficient state in the brain that further ensures the dysfunction of ATP-dependent ion pumps, accumulation of sodium ions (causing cell swelling), increased calcium influx, and hyperexcitability [47]. The augmentation of cytoplasmic calcium levels is the primary mechanism of ROS and RNS output and the activation of calcium-dependent cell demise pathways through the activation of proteases and calpains [48]. In neurodegenerative diseases, free radicals, calcium, lipid peroxidation, and DNA mutlation are at the core of the pathogenic progression of diseases. In previous studies, the analysis of the biomarkers of oxidative stress revealed the amplification of MDA, 4-HNE, and 8-hydroxy-2′-deoxyguanosine (8-OHdG) in the cerebrospinal fluid, brain, and blood samples [49, 50]. In the current experiments, DSM (50 and 100 mg/kg) significantly abrogated QA-ICV-triggered intensification in lipid peroxidation and total nitrates in the mitochondrial portion of the brain. Earlier reports also substantiate the free radical attenuating and anti-inflammatory deeds of DSM in the entire brain of experimental animals [16–20]. The standard drug, DNP, also attenuated the lipid peroxidation (TBARS) and total nitrates in the brain of rats exposed to QA-ICV.

The mitochondria, peroxisomes, endoplasmic reticulum, and plasma membranes are the chief locations of ROS and RNS biosynthesis [51]. Cellular respiration in the mitochondria is the chief generator of ROS, such as superoxide and hydroxyl radicals. Peroxinsomes are the central hub for hydrogen peroxide generation. Superoxide anion acquires an electron from molecular oxygen and dismutates to hydrogen peroxide via the Fenton reaction. Subsequently, this hydrogen peroxide is metabolized by catalase to water and oxygen, or it may generate hydroxyl radical. H2O2 can also generate toxic hydroxyl radicals through the Haber-Weiss reaction. Superoxide anion, by reacting with nitric oxide, can form peroxynitrates [52, 53]. These free radicals trigger mitochondrial permeability transition pore (mPTP), leading to the leakage of cytochrome c, mitochondrial degeneration, and cell demise. Mitochondrial complex I is the gateway for electrons’ entry from NADH into the respiratory chain. Complex I and II can generate superoxide anions in surplus in response to a higher NADH/NAD+ ratio, leading to an abridged FMN (flavin mononucleotide) site on complex I, and electron contribution to the succinate dehydrogenase (SDH)-reduced coenzyme Q is associated with a high proton motive force, leading to reverse electron transport [54]. QA is a well-recognized inhibitor of mitochondrial functions [5]. In this study, QA-ICV caused the inhibition of the brain mitofragment complex I and II rates in rats. The QA-induced aberrations in the mitochondrial electron transport chain functions might be the primary cause of oxidative mutilation in the brain of rats. However, DSM (50 and 100 mg/kg) resurrected the brain complex I and II activities in QA-ICV-challenged rats. DNP treatment also showed significant improvement in complex I and II functions in the brain mitochondria against QA-ICV mitotoxicity. The analysis of antioxidant levels revealed that DSM treatment for 21 consecutive days attenuated QA-ICV-induced decline in endogenous antioxidants, such as GSH, GPx, SOD, and catalase. SOD, catalase, and thiol-dependent antioxidants,

Figure 7: Effect of diosmin (DSM) treatment (doses 50 and 100 mg/kg) on QA-ICV prompted neurodegenerative deviations in the cortical and hippocampus sections (n = 5) (H&E stain, × 40, scale 10 μm). Pyknosis (p), bulging of the plasma membrane (b), and swelling (s) were observed.
such as GSH and GPx, are the 1st line of defense against oxidative mutilation. SOD and catalase detoxify superoxide anions and \( \text{H}_2\text{O}_2 \) respectively, and GPx and GSH are involved in the removal of \( \text{H}_2\text{O}_2 \) and breakdown of lipid peroxides (MDA, 4-HNE, etc.) to their respective alcohols, particularly in the mitochondria and cytoplasm [55]. In the current study, DSM (50 and 100 mg/kg) or DNP regimens boosted the antioxidant actions in the brain of rats that were rendered toward QA-ICV neurotoxicity.

Neuroprotection by DSM and DNP was evident in the H&E staining analysis of hippocampus and cortical regions of rat brains. QA-ICV treatment caused marked changes in the cellular architecture highlighted by pyknosis, cell swelling, and blebbing of the plasma membrane. These pathogenic changes were attenuated by DSM and DNP treatments in separate groups of rats. In the current protocol, DSM (100 mg/kg) showed significant improvement in biochemical parameters against QA-ICV and also attenuated pathological cell mutilation evident in histological analysis in comparison to DSM (50 mg/kg). Hence, these findings depicted the dose-dependent effects of DSM in the QA-ICV rat model of neurodegeneration.

In the weekly analysis, a significant decline in mean body mass (g), feed, and water ingestion was pragmatic in QA-ICV treated rats. Motor coordination (rotarod test) and gait (footprint analysis) were also adversely affected in rats treated with QA-ICV alone. Locomotor activity was not affected by diverse drug treatments in the current set of experiments. However, DSM or DNP treated rats showed significant improvement in motor coordination and gait against QA-ICV toxicity. Body bulk (g), diet, and water consumption were also enhanced by DSM or DNP in separate groups of QA-ICV treated rats. Memory parameters were assessed using NORT (day 16) and MWM (days 17–21) paradigms. A decline in discrimination ability of QA-ICV treated rats in NORT supported loss of working memory. In MWM trials, QA-ICV caused an increase in ELT during four day trials and a decrease in TSTQ in retrieval trials on the 5th day. These findings showed the depreciation of long-term spatial memory of rats by QA-ICV treatment. DSM or DNP treatments attenuated the decline of discrimination index, TSTQ, and increase in ELT in rats that were challenged with QA-ICV on day 1. The contemporary findings are in harmony with the former reports substantiating the memory improvement activity of DSM in experimental animals [16–20]. DSM (100 mg/kg) showed dose-dependent improvement in working memory and long-term memory in comparison to DSM (50 mg/kg) against QA-ICV. The findings showed that DSM could ameliorate brain functions such as memory, motor coordination, and gait in rats in the QA-ICV model. Diosmin is a flavonoid glycoside possessing a sugar moiety (rutinoside disaccharide) and aglycone group diosmetin. In several preclinical studies, diosmin is administered through the parenteral route (i.p.) [17,56], and there is an impending urgency to find a suitable formulation to better translate the pre-clinical findings in clinical settings. Particle size reduction and increasing the surface area can be utilized to enhance its transport across the biological barriers [57].

In this context, a micronized diosmin formulation [58] was attempted that showed greater bioavailability and pharmacokinetic characteristics, however, the targeted brain-specific delivery of diosmin is still a huge challenge.

5. Conclusions

In the current therapeutic scenario where no such drug is available that can revive the pathogenic evolution of neurodegenerative conditions, such as AD and HD, a shift toward natural remedies is pragmatic. Current therapeutic strategies focus on symptomatic improvement only, and none is able to reverse the sequence of the disease development. We observed that diosmin resurrected cognitive functions (working and long-term spatial memory) in the QA-ICV rat model of neurodegeneration. Diosmin improved the sensorimotor performance and the gait of rats against QA-ICV. The observed improvement of behavioral functions in QA-ICV rats treated with diosmin is primarily because of the attenuation of mitochondrial dysfunctions and oxidative mutilation of the brain. Hence, diosmin might be used as an alternative therapeutic agent against mitochondrial dysfunction origin neurodegenerative disorders. However, additional investigations are mandatory to envisage its neuroprotective mechanism and applications in clinical settings.

Data Availability

The data of this study are accessible upon an appropriate demand from the corresponding author.

Ethical Approval

The entire set of animal experimentation was approved by the IAEC (Approval no. ASCB/IAEC/14/20/145) and was executed by implementing the ethical guidelines on animal testing issued by the “Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), GOI, New Delhi.”

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] T. Heinbockel and B. Antonei: Introductory Chapter: The Chemical Basis of Neural Function and Dysfunction, Neurochemical Basis of Brain Function and Dysfunction.
[2] A. V. Eapen, D. Fernández-Fernández, J. Georgiou et al., “Multiple roles of GluN2D-containing NMDA receptors in short-term potentiation and long-term potentiation in mouse hippocampal slices,” Neuropharmacology, vol. 201, p. 108833, 2021.
[3] A. Singh, R. Kukreti, L. Saso, and S. Kukreti, “Oxidative stress: a key modulator in neurodegenerative diseases,” Molecules, vol. 24, no. 8, p. 1583, 2019.
[4] J. Song, X. Yang, M. Zhang, C. Wang, and L. Chen, “Glutamate metabolism in mitochondria is closely related to...
alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 84, no. 2, pp. 557–578, 2021.

[5] R. Lugo-Huitrón, P. Ugalde Muñiz, B. Pineda, J. Pedraza-Chaverri, C. Ríos, and V. Pérez-de la Cruz, “Quinolinic acid: an endogenous neurotoxin with multiple targets,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 104024, 14 pages, 2013.

[6] T. W. Stone and L. G. Darlington, “The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders,” British Journal of Pharmacology, vol. 169, no. 6, pp. 1211–1227, 2013.

[7] V. K. Sharma, T. G. Singh, N. K. Prabhakar, and A. Mannan, “Kyunurenine metabolism and alzheimer’s disease: the potential targets and approaches,” Neurochemical Research, 2022.

[8] D. C. Maddison and F. Giorgini, “The kynurenine pathway and neurodegenerative disease,” Seminars in Cell & Developmental Biology, vol. 40, pp. 134–141, 2015.

[9] Y. Liang, S. Xie, Y. He et al., “Kynurenine pathway metabolites as biomarkers in alzheimer’s disease,” Disease Markers, vol. 2022, Article ID 9484217, 15 pages, 2022.

[10] G. J. Guillemin, “Quinolinic acid, the inescapable neurotransin,” FEBS Journal, vol. 279, no. 8, pp. 1356–1365, 2012.

[11] M. K. Arora, A. Kisku, and A. Jangra, “Mangiferin ameliorates intracerebroventricular-quinolinic acid-induced cognitive deficits, oxidative stress, and neuroinflammation in Wistar rats,” Indian Journal of Pharmacology, vol. 52, no. 4, pp. 296–305, 2020.

[12] M. Sharifi-Rad, C. Lankatillake, D. A. Dias et al., “Impact of natural compounds on neurodegenerative disorders: from preclinical to pharmacotherapeutics,” Journal of Clinical Medicine, vol. 9, no. 4, p. 1061, 2020.

[13] N. S. Mohd Sairazi and K. N. S. Sirajudeen, “Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases,” Evidence-based Complementary and Alternative Medicine, vol. 2020, Article ID 6565396, 30 pages, 2020.

[14] S. Srinivasan, V. Vinothkumar, and R. Murali, “Antidiabetic efficacy of citrus fruits with special allusion to flavone glycosides,” Bioactive Food as Dietary Interventions for Diabetes, vol. 1, pp. 335–346, 2019.

[15] S. H. Gerges, S. A. Wahdan, D. A. Elsherbyni, and E. El-Demerdash, “Pharmacology of diosmin, a citrus flavone glycoside: an updated review,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 47, no. 1, pp. 1–18, 2021.

[16] M. A. Mirshekar, H. Fanaei, F. Keikhaei, and F. S. Javan, “Diosmin improved cognitive deficit and amplified brain electrical activity in the rat model of traumatic brain injury,” Biomedicine & Pharmacotherapy, vol. 93, pp. 1220–1229, 2017.

[17] S. Shabani and M. A. Mirshekar, “Diosmin is neuroprotective in a rat model of scopalamine-induced cognitive impairment,” Biomedicine & Pharmacotherapy, vol. 108, pp. 1376–1383, 2018.

[18] A. Okubo Eneni, B. Ben-Azu, A. Mayowa Ajayi, and A. Oladele Aderibigbe, “Diosmin attenuates schizophrenialike behavior, oxidative stress, and acetylcholinesterase activity in mice,” Drug Metabolism and Personalized Therapy, vol. 35, no. 4, p. 20200119, 2020.

[19] E. Saghaei, S. Nasiri Boroujeni, P. Safavi, Z. Borjian Boroujeni, and E. Bijad, “Diosmetin mitigates cognitive and memory impairment provoked by chronic unpredictable mild stress in mice,” Evidence-based Complementary and Alternative Medicine, vol. 2020, Article ID 5725361, 10 pages, 2020.

[20] D. Sawmiller, A. Habib, S. Li et al., “Diosmin reduces cerebral Aβ levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice,” Journal of Neuroimmunology, vol. 299, pp. 98–106, 2016.

[21] G. Pazinos, C. R. R. Watson, and P. C. Emson, “AChE-stained horizontal sections of the rat brain in stereotaxic coordinates,” Journal of Neuroscience Methods, vol. 3, no. 2, pp. 129–149, 1980.

[22] R. A. Santana-Martínez, C. A. Silva-Islas, Y. Y. Fernández-Orihuela et al., “The therapeutic effect of curcumin in quinolinic acid-induced neurotoxicity in rats is associated with BDNF, ERK1/2, Nrf2, and antioxidant enzymes,” Antioxidants, vol. 8, no. 9, p. 388, 2019.

[23] M. Kumar and N. Bansal, “Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer’s disease: involvement of PI3-kinase, eNOS and NFkB,” Behavioural Brain Research, vol. 351, pp. 4–16, 2018.

[24] A. Ennaceur and J. Delacour, “A new one-trial test for neurobiological studies of memory in rats: 1: behavioral data,” Behavioural Brain Research, vol. 31, no. 1, pp. 47–59, 1988.

[25] M. Kumar and N. Bansal, “Caffeic acid phenethyl ester rescues streptozotocin-induced memory loss through PI3-kinase dependent pathway,” Biomedicine & Pharmacotherapy, vol. 101, pp. 162–173, 2018.

[26] R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, no. 1, pp. 47–60, 1984.

[27] R. Sandhiri, A. Mehrotra, and S. S. Kamboj, “Lycopene prevents 3-nitripotin acid-induced mitochondrial oxidative stress and dysfunctions in nervous system,” Neurochemistry International, vol. 57, no. 5, pp. 579–587, 2010.

[28] T. E. King and R. L. Howard, “[52] Preparations and properties of soluble NADH dehydrogenases from cardiac muscle,” Methods in Enzymology, vol. 10, pp. 275–294, 1967.

[29] T. E. King, “[58] Preparation of succinate dehydrogenase and reconstitution of succinate oxidase,” Methods in Enzymology, vol. 10, pp. 322–331, 1967.

[30] H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thioarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979.

[31] G. L. Ellman, “Tissue sulphydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959.

[32] J. Mohandas, J. S. Tyagi, and R. J. Randall, “Differential distribution of glutathione and glutathione-related enzymes in rabbit kidney,” Biochemical Pharmacology, vol. 33, no. 11, pp. 1801–1807, 1984.

[33] P. Kakkar, B. Das, and P. N. Viswanathan, “A modified spectrophotometric assay of superoxide dismutase,” Indian Journal of Biochemistry & Biophysics, vol. 21, pp. 130–132, 1984.

[34] A. Claiborne, “Catalase activity,” in CRC Handbook of Methods for Oxygen Radical Research, R. A. Greenwald, Ed., CRC Press, Boca Raton, FL, USA, 1985.

[35] K. V. H. Sastry, R. P. Moudgal, J. Mohan, S. T. Yagi, and G. S. Rao, “Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy,” Analytical Biochemistry, vol. 306, no. 1, pp. 79–82, 2002.

[36] T. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the folin phenol reagent,” Journal of Biological Chemistry, vol. 193, pp. 265–275, 1951.

[37] R. L. Auten and J. M. Davis, “Oxygen toxicity and reactive oxygen species: the devil is in the details,” Pediatric Research, vol. 66, no. 2, pp. 121–127, 2009.

[38] M. Shichiri, “The role of lipid peroxidation in neurological disorders,” Journal of Clinical Biochemistry & Nutrition, vol. 54, no. 3, pp. 151–160, 2014.
M. C. Martínez and R. Andriantsitohaina, “Reactive nitrogen species: molecular mechanisms and potential significance in health and disease,” *Antioxidants and Redox Signaling*, vol. 11, no. 3, pp. 669–702, 2009.

F. Taqatqeh, E. Mergia, A. Neitz, U. T. Eysel, D. Koesling, and T. Mittmann, “More than a retrograde messenger: nitric oxide needs two cGMP pathways to induce hippocampal long-term potentiation,” *Journal of Neuroscience*, vol. 29, no. 29, pp. 9344–9350, 2009.

P. K. Kamat, A. Kalani, S. Rai et al., “Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer’s disease: understanding the therapeutics strategies,” *Molecular Neurobiology*, vol. 53, no. 1, pp. 648–661, 2016.

X. Gao, X. Xu, J. Pang et al., “NMDA receptor activation induces mitochondrial dysfunction, oxidative stress and apoptosis in cultured neonatal rat cardiomyocytes,” *Physiological Research*, vol. 56, no. 5, pp. 559–569, 2007.

H. Girouard, G. Wang, E. F. Gallo et al., “NMDA receptor activation increases free radical production through nitric oxide and NOX2,” *Journal of Neuroscience*, vol. 29, no. 8, pp. 2545–2552, 2009.

X.-m. Chen, H.-s. Chen, M.-j. Xu, and J.-g. Shen, “Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury,” *Acta Pharmacologica Sinica*, vol. 34, no. 1, pp. 67–77, 2013.

L. E. Jones Jr, L. Ying, A. B. Hofseth et al., “Differential effects of reactive nitrogen species on DNA base excision repair initiated by the alkyladene DNA glycosylase,” *Carcinogenesis*, vol. 30, no. 12, pp. 2123–2129, 2009.

N. Kaludercic and V. Giorgio, “The dual function of reactive oxygen/nitrogen species in bioenergetics and cell death: the role of ATP synthase,” *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3869610, 17 pages, 2016.

C. B. Rueda, I. Llorente-Folch, J. Traba et al., “Glutamate excitotoxicity and Ca2+ - regulation of respiration: role of the Ca2+ activated mitochondrial transporters (CaMGs),” *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, vol. 1857, no. 8, pp. 1158–1166, 2016.

X. Wang, W. Wang, L. Li, G. Perry, H.-g. Lee, and X. Zhu, “Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease,” *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1842, no. 8, pp. 1240–1247, 2014.

S. Dalleau, M. Baradat, F. Gue´raud, and L. Huc, “Cell death and diseases related to oxidative stress/4-hydroxynonenal (HNE) in the balance,” *Cell Death & Differentiation*, vol. 20, no. 12, pp. 1615–1630, 2013.

E. Niedzielska, I. Smaga, M. Gawlik et al., “Oxidative stress in neurodegenerative diseases,” *Molecular Neurobiology*, vol. 53, no. 6, pp. 4094–4125, 2016.

D. B. Zorov, M. Juhasztova, and S. I. Sollott, “Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release,” *Physiological Reviews*, vol. 94, no. 3, pp. 909–950, 2014.

R. Z. Zhao, S. Jiang, L. Zhang, and Z. B. Yu, “Mitochondrial electron transport chain, ROS generation and uncoupling (Review),” *International Journal of Molecular Medicine*, vol. 44, no. 1, pp. 3–15, 2019.

M. P. Murphy, “How mitochondria produce reactive oxygen species,” *Biochemical Journal*, vol. 417, no. 1, pp. 1–13, 2009.

L. He, T. He, S. Farrar, L. Ji, T. Liu, and X. Ma, “Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species,” *Cellular Physiology and Biochemistry*, vol. 44, no. 2, pp. 532–553, 2017.